Pharmafile Logo

severe hypertriglyceridemia

- PMLiVE

ICER extends evaluation of Biogen’s aducanumab after FDA delay

FDA delayed its decision on potential Alzheimer's therapy to 7 June

- PMLiVE

NIH trial of AZ’s long-acting COVID-19 antibody launches in the US

Study will evaluate efficacy of drug in patients hospitalised with COVID-19

- PMLiVE

FDA grants emergency use for Lilly’s COVID-19 antibody drug combination

Bamlanivimab plus etesevimab shown to reduce risk of death in high-risk COVID-19 patients

- PMLiVE

FDA considers new safety warnings for Pfizer’s JAK inhibitor Xeljanz

Post-marketing study shows increased risk of serious heart-related problems and cancer with Xeljanz

- PMLiVE

FDA schedules meeting on 26 February to review J&J’s one-dose COVID-19 vaccine

Vaccine candidate demonstrated an overall efficacy of 66% in phase 3

- PMLiVE

South Africa puts AZ/Oxford COVID-19 vaccine roll-out on hold

Pre-print study results found jab offers 'minimal' protection against B.1.351 variant

- PMLiVE

Rolling reviews of Novavax’s COVID-19 vaccine begin across the globe

And the FDA is planning rapid reviews for COVID-19 vaccine boosters

- PMLiVE

UK launches world-first COVID-19 study evaluating a mixed-vaccine regimen

Participants could receive AZ/Oxford University's vaccine for their first dose and Pfizer/BioNTech's vaccine for their second

- PMLiVE

EU may restrict exports of some COVID-19 vaccines

Proposed strategy follows a confrontation between the EU and AstraZeneca

- PMLiVE

The UK reasserts that the AZ vaccine is ‘effective across all age groups’

Germany's draft guidance does not recommend the vaccine for people over 65

- PMLiVE

AZ and EU fail to solve COVID-19 vaccine delivery issues

AZ temporarily reduced Q1 deliveries to the EU last week

- PMLiVE

AZ refutes reports suggesting its COVID-19 vaccine is less effective in the elderly

German media reports suggested vaccine is less than 10% effective in the elderly

Subscribe to our email news alerts

Latest jobs from #PharmaRole

Latest content

Latest intelligence

Quick links